Lupin ZXR 60 Tablet contains Gliclazide 60 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. This medication is typically prescribed when diet, exercise, and weight reduction alone are insufficient to achieve adequate blood glucose levels. Gliclazide exhibits a selective action on pancreatic receptors, which contributes to a reduced risk of hypoglycemia compared to other sulfonylureas. Lupin ZXR 60 Tablet should be administered once daily with breakfast to optimize absorption and minimize adverse effects. It is essential to monitor blood glucose levels regularly to adjust the dosage appropriately and prevent hypoglycemic episodes. Common side effects may include mild gastrointestinal disturbances, skin reactions, or hypoglycemia, especially if meals are skipped or excessive physical activity occurs. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to sulfonylureas. Lupin ZXR 60 Tablet is a valuable therapeutic option for improving glycemic control and reducing the risk of diabetes-related complications when used as part of a comprehensive diabetes management plan.